SCHEMBL2876451

SCHEMBL2876451

N#Cc1c[nH]n2c(Nc3ccc4c(c3)OCO4)c(-c3ccccn3)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.54
▸ GAA P10253 7/20 0.54
▸ KMT2A Q03164 4/20 0.54
▸ L3MBTL1 Q9Y468 3/20 0.54
▸ POLB P06746 3/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ USP2 O75604 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ PPP1CA P62136 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ TGFBR1 P36897 2/20 0.42
▸ MAPK13 O15264 1/20 0.42
▸ MAPK12 P53778 1/20 0.42
▸ MAPK11 Q15759 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ TP53 P04637 5/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2873341 0.86 TGFBR1 (0.45) MAPTGAAKMT2AL3MBTL1POLB
SCHEMBL2122331 0.82 ABCG2 (0.47) MAPTGAAKMT2ASMN1; SMN2LMNA
SCHEMBL2123121 0.81 MAPT (0.54) MAPTGAAPOLBSMN1; SMN2LMNA
SCHEMBL2122218 0.81 MAOB (0.44) MAPTGAAKMT2AL3MBTL1POLB
SCHEMBL2123221 0.79 MAPT (0.55) MAPTGAAPOLBSMN1; SMN2LMNA
SCHEMBL2124513 0.79 LMNA (0.41) MAPTGAASMN1; SMN2LMNAHTT
SCHEMBL2132433 0.79 MAPT (0.41) MAPTGAAKMT2ASMN1; SMN2LMNA
SCHEMBL2125958 0.79 KDM5A (0.48) MAPTGAASMN1; SMN2LMNAHTT
SCHEMBL2126473 0.79 MAPT (0.43) MAPTGAAKMT2APOLBMEN1
SCHEMBL2124362 0.78 MAPT (0.43) MAPTGAAPOLBLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK MAPT 4045/4885GAA 502/4885KMT2A 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback